Endothelial, Vascular and Sympathetic Alterations as Therapeutic Targets in Chronic Heart Failure

Biomedicines. 2023 Mar 6;11(3):803. doi: 10.3390/biomedicines11030803.

Abstract

Vascular and sympathetic abnormalities characterize chronic heart failure (CHF). Alterations include (1) a reduction in arterial distensibility, (2) endothelial dysfunction, (3) a decrease in arterial compliance and a parallel increase in arterial stiffness, and (4) sympathetic cardiovascular activation. Altogether, these alterations represent important targets in therapeutic interventions, because they display an independent negative impact on the disease prognosis, favouring disease progression and the development of cardiovascular complications with direct and indirect mechanisms. The present review will examine the effects of the different therapeutic interventions targeting the vascular/sympathetic alterations detected in CHF. Non-pharmacological, pharmacological and device-based treatments will be discussed in detail, highlighting the possible mechanisms responsible for the vascular/sympathetic effects of each intervention. Finally, the unmet goals in treatment in relation to endothelial and adrenergic targets will be also discussed.

Keywords: cardiovascular drugs; carotid baroreceptor stimulation; chronic heart failure; endothelial function; physical training; rehabilitation; renal denervation; sympathetic activity.

Publication types

  • Review

Grants and funding

This research received no external funding.